Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 90

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 90
---
, and prospects for growth could suffer.

If we fail to comply with our obligations in the agreements under which we license IP rights from other parties or otherwise experience disruptions to our business relationships with our licensors, we could be required to pay monetary damages or could lose license rights that are important to our business.

Many of our projects (including
our Lead Projects) are based on IP which we have licensed from other parties. (See “Intellectual Property”) Certain of these
license agreements impose diligence, development or commercialization obligations on us, such as obligations to pay royalties on net product
sales of our drug candidates once commercialized by us, to pay a percentage of sublicensing revenues if the licensed product is sublicensed,
to make other specified milestone and/or annual payments relating to our drug candidates or to pay license maintenance and other fees,
as well as obligations to pursue commercialization with due diligence. Specifically, a number of our license agreements also require us
to meet development timelines in order to maintain the related license(s). In spite of our efforts, our licensors might conclude that
we have materially breached our obligations under such license agreements and might therefore seek to terminate the license agreements.
If one of our licensors, despite our efforts, were to be successful in terminating its agreement with us, we would not be able to continue
to develop, manufacture or market any drug candidate under that license agreements, and we could face claims for monetary damages or other
penalties under that agreement. Such an occurrence would diminish or eliminate the value of that project to our Company, even if we are
able to negotiate new or reinstated agreements, which may have less favorable terms. Depending on the importance of the IP and the related
project, any such development could have a material adverse effect on our competitive position, business, financial conditions, results
of operations, and prospects.

Moreover, disputes may arise regarding
intellectual property subject to a licensing agreement, including:

| ● | the scope of rights granted under the license agreement and 
 other interpretation-related issues;                        |

| ● | the extent to which our technology and processes infringe on                          
 intellectual property of the licensor that is not subject to the licensing agreement; |

| ● | the sublicensing of patent and other rights under our collaborative 
 development relationships;                                          |

| ● | our diligence obligations under the license agreement and what 
 activities satisfy those diligence obligations;                |

| ● | the inventorship and ownership of inventions and know-how resulting                                   
 from the joint creation or use of intellectual property by our licensors